The estimated Net Worth of Catherine A. Knupp is at least $17.6 Milión dollars as of 10 November 2021. Catherine Knupp owns over 10,000 units of Zoetis Inc stock worth over $8,291,544 and over the last 12 years he sold ZTS stock worth over $6,035,956. In addition, he makes $3,311,220 as Executive Vice President a President - Research and Development at Zoetis Inc.
Catherine has made over 11 trades of the Zoetis Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 10,000 units of ZTS stock worth $2,171,900 on 10 November 2021.
The largest trade he's ever made was exercising 46,816 units of Zoetis Inc stock on 15 August 2018 worth over $1,446,146. On average, Catherine trades about 2,994 units every 42 days since 2013. As of 10 November 2021 he still owns at least 43,642 units of Zoetis Inc stock.
You can see the complete history of Catherine Knupp stock trades at the bottom of the page.
Dr. Catherine A. Knupp is Executive Vice President, President - Research and Development of Zoetis Inc. Dr. Knupp has served as our Executive Vice President and President of Research and Development since October 2012. From 2005 to 2012, she served as Vice President of Pfizer’s Veterinary Medicine Research and Development business unit. Dr. Knupp joined Pfizer in July 2001 and held various positions, including Vice President of Pfizer’s Michigan laboratories for Pharmacokinetics, Dynamics and Metabolism.
As the Executive Vice President a President - Research and Development of Zoetis Inc, the total compensation of Catherine Knupp at Zoetis Inc is $3,311,220. There are 2 executives at Zoetis Inc getting paid more, with Glenn David having the highest compensation of $3,672,350.
Catherine Knupp is 59, he's been the Executive Vice President a President - Research and Development of Zoetis Inc since 2012. There are 9 older and 13 younger executives at Zoetis Inc. The oldest executive at Zoetis Inc is William Steere, 83, who is the Independent Director.
Catherine's mailing address filed with the SEC is C/O ZOETIS INC., 10 SYLVAN WAY, PARSIPPANY, NJ, 07054.
Over the last 12 years, insiders at Zoetis Inc have traded over $876,669,659 worth of Zoetis Inc stock and bought 1,602,140 units worth $77,083,975 . The most active insiders traders include Square Capital Management, ..., Frank A Damelio a Michael B Mccallister. On average, Zoetis Inc executives and independent directors trade stock every 14 days with the average trade being worth of $14,414,921. The most recent stock trade was executed by Soria Ester Banque on 31 July 2024, trading 895 units of ZTS stock currently worth $170,041.
Zoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.
Zoetis Inc executives and other stock owners filed with the SEC include: